Takeda joins consortium that accelerates R&D for malaria, TB vaccines

On Monday, Takeda announced its participation in WIPO Re:Search, a consortium to accelerate research and development of new drugs, vaccines and diagnostics for malaria and tuberculosis. "Takeda's participation in the consortium demonstrates our commitment to supporting better access to medicines for people around the world, including those in emerging markets and developing counties," said Isabel Torres, Takeda's director, access to medicines, in a statement. WIPO Re:Search was established in 2011 by the World Intellectual Property Organization and BIO ventures for Global Health. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.